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Purpose: To explore the utility of phosphorus magnetic resonance spectroscopy (31P
MRS) in identifying anthracycline-induced cardiac toxicity in patients with breast cancer.
Methods: Twenty patients with newly diagnosed breast cancer receiving
anthracycline-based chemotherapy had cardiac magnetic resonance assessment
of left ventricular ejection fraction (LVEF) and 31P MRS to determine myocardial
Phosphocreatine/Adenosine Triphosphate Ratio (PCr/ATP) at three time points:
pre-, mid-, and end-chemotherapy. Plasma high sensitivity cardiac troponin-I (cTn-I)
tests and electrocardiograms were also performed at these same time points.
Results: Phosphocreatine/Adenosine Triphosphate did not change significantly
between pre- and mid-chemo (2.16 ± 0.46 vs. 2.00 ± 0.56, p = 0.80) and pre- and
end-chemo (2.16± 0.46 vs. 2.17± 0.86, p= 0.99). Mean LVEF reduced significantly by
5.1% between pre- and end-chemo (61.4 ± 4.4 vs. 56.3 ± 8.1 %, p = 0.02). Change in
PCr/ATP ratios from pre- to end-chemo correlated inversely with changes in LVEF over
the same period (r = −0.65, p = 0.006). Plasma cTn-I increased progressively during
chemotherapy from pre- to mid-chemo (1.35 ± 0.81 to 4.40 ± 2.64 ng/L; p = 0.01) and
from mid- to end-chemo (4.40 ± 2.64 to 18.33 ± 13.23 ng/L; p = 0.001).
Conclusions: In this small cohort pilot study, we did not observe a clear change in mean
PCr/ATP values during chemotherapy despite evidence of increased plasma cardiac
biomarkers and reduced LVEF. Future similar studies should be adequately powered to
take account of patient drop-out and variable changes in PCr/ATP and could include T1
and T2 mapping.
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INTRODUCTION
Anthracyclines are widely used in the treatment of breast cancer
and are well-recognized to carry increased risk of cardiotoxicity
(1–3). This can occur as an early, acute manifestation, or
many years after treatment as late onset cardiomyopathy (4,
5). It is increasingly apparent that there may be a chronic
subclinical phase associated with low grade cardiac injury
with no apparent clinical impact on the contractile function
of the heart (6). This period may remain latent for many
years with the patient remaining asymptomatic and with
apparently normal cardiac function. Identification of early and
subtle cardiac dysfunction during this period could provide a
window of opportunity for therapeutic intervention if those
at risk or those experiencing this low-grade decline could
be accurately identified. Recent studies have suggested that it
might be possible to detect subclinical cardiac dysfunction using
echocardiographic strain measurements of the left ventricle and
that such changes might predict future risk of developing cardiac
dysfunction (7, 8). Other studies have suggested that plasma
levels of cardiac troponin could also provide a useful marker
of early and ongoing cardiac injury following anthracycline
treatment (9, 10).
Left Ventricular Ejection Fraction (LVEF), assessed by a
variety of imaging methods, is recognized as insensitive for the
detection of early anthracycline-induced cardiomyopathy (11).
The widely used values for a clinically relevant decline in ejection
fraction associated with clinical symptoms of heart failure, or
an asymptomatic decrease in LVEF of 10% to <55% (10, 12)
represent a relatively late manifestation of cardiac toxicity. In
some cases, by the time a reduction in LVEF occurs the patient
may have irreversible cardiac damage. As cancer survival rates
increase there is a clear need not only to identify early markers
of anthracycline myocardial toxicity but also to explore new
techniques that could potentially identify baseline characteristics,
pre-chemotherapy, that might predict the likelihood of
developing subsequent cardiotoxicity. An accurate method of
identifying, and possibly even predicting, early cardiac toxicity
could aid oncologists in optimizing chemotherapy treatment
whilst limiting the short and long-term cardiotoxic effects of
these agents.
This study explores the potential utility of phosphorus
magnetic resonance spectroscopy (31P-MRS) acquired using
a clinical 3T MR system to identify early anthracycline-
induced cardiac toxicity and baseline predisposition to cardiac
injury. This technique measures the phosphocreatine/adenosine
triphosphate concentration ratio (PCr/ATP), which reflects
cardiac cellular energetics. The normal range of PCr/ATP is
approximately 1.8–2.2, whereas decreased PCr/ATP is associated
with a drop in available energy reserve in the heart, associated
with many forms of heart failure (13, 14).
Conventional cardiac investigations of electrocardiogram
and ultra-high sensitivity plasma cardiac troponin-I (cTn-
I) have also been applied. To our knowledge PCr/ATP
has not previously been used sequentially to assess cardiac




This study was approved by the South East Scotland Research
Ethics Committee (14/SS/1041) and all participants gave full
written informed consent.
Study Population and Recruitment
Twenty female breast cancer patients with no prior exposure
to anthracyclines scheduled to receive anthracycline-based
chemotherapy either in the adjuvant or the neoadjuvant setting
were recruited from the Breast clinic at the South East Scotland
Cancer Center over a period of 18 months. The combination
chemotherapy regimens were either six cycles of adjuvant FEC-
80 [Fluorouracil, Epirubicin (80 mg/m3), cyclophosphamide],
or three cycles of FEC [Fluorouracil, Epirubicin (100 mg/m3),
cyclophosphamide] followed by three cycles of Docetaxel (FEC-
T). Four patients had a history of hypertension: two treated
with ramipril and two with bendroflumethiazide (Table 1).
None of the patients had coronary heart disease, diabetes,
hypercholesterolemia, or heart failure at baseline.
The mean time between each scan was 7 weeks (range 6–
12 weeks) and was designed flexibly to allow for the oncology
team to defer or postpone the next chemo-treatment for clinical
reasons including chemotherapy-related side effects including
nausea, fatigue, and general malaise.
Thirteen healthy volunteers (48.8 ± 11.2 years, range 31–60)
with no background medical conditions and on no medications
underwent a single MRI imaging protocol and a single 31P
MRS as described for patients. Phosphocreatine/Adenosine
Triphosphate Ratios and left ventricular ejection fraction
were calculated for each volunteer. Scanning was repeated
for three of these normal subjects to assess repeatability of
measurements. The maximum difference between repeated
PCr/ATP measurements and repeated LVEF measurements for
volunteers defined the cut-off above which a real change
could be assumed to occur in patients between pre- to mid-
chemotherapy, mid- to end-chemotherapy, and pre- to end-
chemotherapy. Volunteers did not undergo ECG or plasma
troponin measurements and did not undergo sequential repeat
MR scans.
High Sensitivity Cardiac Troponin-I (cTn-I)
Measurements
Blood samples were taken immediately prior to the first and
fourth chemotherapy cycles and within 2 weeks of completion of
the sixth chemotherapy cycle. Plasma Cardiac Tn-I wasmeasured
using a high sensitivity assay (ARCHITECT STAT Troponin I
assay; Abbott Laboratories). This assay has a limit of detection
of 1.2 ng/L, with a coefficient of variation of 23% at the limit
of detection (1.2 ng/L) and <10% at 6 ng/L (15). The upper
reference limit, determined by the manufacturer as the 99th
centile of samples from 4,590 healthy individuals, is 16 ng/L
in women (15). As part of clinical follow-up, cTn-I was also
measured within 3 months of completion of chemotherapy in
patients where values increased above the normal range (0–16
ng/l) at any time point during chemotherapy.
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TABLE 1 | Patient population clinical characteristics and treatment regimens.
Patient Age range (years) Smoking history BMI Menopausal status Hyper-tension Chemo-therapy Trastuzumab Cancer side Radiotherapy
1 60–70 No 28 Post No FEC-T No R Yes
2 60–70 No 31 Post No FEC No R Yes
3 40–50 No 24 Pre No FEC-T No R No
4 50–60 No 31 Post No FEC80 No L Yes
5 40–50 Yes 28 Pre No FEC-T No R Yes
6 50–60 No 38 Post No FEC-T No L Yes
7 30–40 No 24 Pre No FEC-T No L No
8 50–60 Yes 32 Post No FEC-T No L Yes
9 60–70 No 26 Post Yes* FEC80 No R Yes
10 50–60 No 25 Pre No FEC-T No R Yes
11 30–40 No 28 Pre No FEC80 No L Yes
12 50–60 No 30 Pre No FEC-T No R Yes
13 50–60 Yes 24 Post No FEC-T Yes L Yes
14 40–50 No 36 Pre No FEC-T No R Yes
15 50–60 No 35 Post Yes* FEC-T No L Yes
16 40–50 No 23 Pre Yes** FEC80 No R Yes
17 50–60 No 27 Post Yes** FEC80 No L Yes
18 40–50 No 26 Pre No FEC-T Yes L+R Yes
19 30–40 Yes 30 Pre No FEC-T No L Yes
20 50–60 No 32 Pre No FEC-T No L Yes
Cardiac history of any of angina, hypertension, previous myocardial infarction, heart failure. Chemotherapy regimen: FEC80—six cycles of Fluorouracil, Epirubicin (80 mg/m3 ),
cyclophosphamide. FEC-T—three cycles of Fluorouracil, Epirubicin, (100 mg/m3), cyclophosphamide followed by three cycles of docetaxel.
*Hypertension treated with ramipril.
**Hypertension treated with Bendroflumethiazide.
FIGURE 1 | 31P-MRS spectrum acquisition. An example of the voxel
positioning for 31P-MRS acquisition spectrum, the spectrum acquired at the
mid-septum, denoted by the red square, is analyzed. An example of a 31P MR
spectrum is also shown (B) with resonances corresponding to
phosphocreatine (PCr), γ, β, and α adenosine triphosphate (ATP), and
2,3-diphosphoglycerate (2,3 DPG) labeled.
Cardiac Magnetic Resonance Imaging
(CMRI)
Participants attended the Edinburgh Imaging QMRI facility at
three time points: pre-, mid-, and end-chemotherapy. Mid-
chemotherapy was defined as between cycles 3 and 4 and
end-chemotherapy was within 27 ± 19 days of completing
cycle 6. On each occasion participants were positioned head
first supine in a 3T Verio MR scanner (Siemens Healthineers,
Erlangen, Germany) between anterior and posterior parts of




The 31P MRS protocol used for this study has been described in
detail elsewhere (16). In brief the total MR protocol acquisition
time including positioning, set-up and acquisition of cine MR
imaging to calculate ejection fraction and MRS was 60min. 31P
MR spectra were acquired over 30min using a 3D UTE-CSI
pulse sequence (TR/TE = 1,000/∼0.6ms, FOV = 350 × 350 ×
350 mm3, 22 × 22 × 10 CSI matrix). A flip angle (α) of 30◦
was applied to the mid-septum of the myocardium. Voxels were
carefully planned so that one full voxel was aligned with the
mid-septum. Figure 1 shows an example of the planning of the
voxel positioning. While spectra are acquired from each voxel,
that acquired from the mid-septum voxel (denoted by the red
square in Figure 1) is the spectrum used for analysis. The 31P
MRS acquisition was not ECG gated.
Analysis of the 31P spectra was carried out using a
custom Matlab implementation of AMARES (17) and was
analyzed by two independent observers blinded to the time-
point of analysis. This analysis quantifies the amount of
phosphocreatine (PCr) and adenosine triphosphate (ATP)
present in the cardiac spectrum as a concentration ratio
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(“PCr/ATP”). The PCr/ATP ratio was corrected for saturation
effects and blood contamination. Phosphocreatine/Adenosine
Triphosphate Ratios were calculated for each of the three
time-points.
Left Ventricular Ejection Fraction
A series of Cardiac Magnetic Resonance (CMR) cine images
were acquired from base to apex in the short axis plane using
the system’s integrated body coil (TrueFISP sequence: TR/TE =
85.8/1.45ms, α = 50◦, FOV = 400 × 338 mm2, matrix = 256
× 205, Grappa acceleration factor = 3, slice thickness = 8mm).
Two independent operators subsequently calculated the LVEF
from these images using QMass R© software (Medis, Leiden, The
Netherlands). This was carried out for images acquired at each
time point.
We used the definition of the Cardiac Review and Evaluation
Committee (CREC) supervising Trastuzumab trials which
defined cardiotoxicity as a decrease in LVEF of 5 points to
<55% with accompanying signs or symptoms of heart failure,
or a decline of 10 points to <55% without heart failure signs or
symptoms (10, 12).
Electrocardiograms
A 12-lead ECG was acquired at each of the three time points
immediately prior to each MRI scan. These were reported
by a Cardiologist and any abnormalities grouped by ST
segment change, left ventricular hypertrophy and changes in the
QT interval.
Statistical Analysis
All statistical analysis was carried out using Minitab 17 Statistical
Software (Minitab 17 Statistical Software (2010), State College,
PA: Minitab, Inc.). Data were analyzed using paired Student’s t-
tests or one-way ANOVA as appropriate. Associations between
various parameters were assessed using Pearson’s Coefficient.
Significance was accepted at p ≤ 0.05.
The mean PCr/ATP ratio for age-matched female healthy
controls was 1.75 ± 0.59 (range 1.11–2.18, n = 13). In three
healthy volunteers with repeat measurements of PCr/ATP the
difference in values between scans were 0.58, 0.53, and 0.20.
This was consistent with other published work suggesting that
a change in PCr/ATP of 0.5, with 95% confidence, could be
detected with a sample size of nine patients using a similar
protocol as that used in patients with heart failure (18). However,
since we could not accurately predict the change in PCr/ATP
associated with the anthracycline regimes used in our patients
we recognized that, taking drop-out into account, we might not
be adequately powered to detect a smaller change in PCr/ATP




All participants were women with median age 51 (range 31–
67 years) and median body mass index 28 (range 23–36). Six
patients (30%) received FEC80, fourteen (70%) received FEC-T
FIGURE 2 | Left ventricular ejection fraction in healthy volunteers and in breast
cancer patients during chemotherapy. Healthy volunteer left ventricular
ejection fraction (LVEF, blue, n = 13) and sequential LVEF in patients (black)
pre- (n = 20), mid- (n = 15), and end-chemotherapy (n = 19) acquired by
cardiac magnetic resonance (CMR) imaging [box and whiskers plot, values are
mean ± SD, and 95% confidence intervals, *P = 0.02 for change from pre-to
end chemo in patients (paired t-test)].
chemotherapy, and eighteen (90%) received radiotherapy. Two
patients treated with the FEC-T received Trastuzumab from the
mid-chemo time point. Ten patients had left sided tumors and
one had left and right sided tumors. Nine participants were
post-menopausal.
All participants attended their pre-chemotherapy MRI scan
while five were unable to attend the mid-chemotherapy scan due
to inter-current illness and one was unable to attend the final
end-chemotherapy MRI scan.
Cardiac Magnetic Resonance Imaging
(CMR)
The mean LVEF for healthy volunteers was 63.6 ± 4.5% with
range 57.6–74.3%. Differences in repeated measurements of
LVEF for three volunteers were 0.5, 0.6, and −0.5%, indicating
a very high degree of repeatability.
Left ventricular ejection fraction was calculated for all 20
participants prior to chemotherapy, 15 at mid-chemotherapy,
and 19 at end-chemotherapy.
The mean (± standard deviation) LVEF at pre-, mid-, and
end-chemotherapy was 61.6 ± 4.4, 60.5 ± 5.2, and 56.3 ± 8.1%
respectively (Figure 2). There was a significant decrease in LVEF
between pre- and end-chemotherapy (p = 0.02). There was no
significant difference in LVEF between patients receiving FEC80
(n = 5) and those receiving FEC-T (n = 12) at mid (57.7 ±
5.6 vs. 61.9 ± 4.7%, respectively, p = 0.14) or end-chemo time-
points (55.9 ± 3.9 vs. 56.5 ± 9.6%, respectively, p = 0.94). Left
ventricular mass did not change significantly between pre-chemo
and end-chemo (83.2± 11.9 vs. 82.0± 10.7g; p= 0.78).
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In total, six patients experienced a significant decrease in LVEF
according to agreed criteria (10). Three symptomatic patients
(with breathlessness) experienced a 5% decrease in LVEF from
pre- to mid-chemo. Two of these patients had no further change
in LVEF from mid- to end-chemo and one had a significant
increase. Three additional patients experienced a decrease of
10% in LVEF from mid- to end-chemo. One patient, receiving
FEC-T, became symptomatic during treatment with associated
ankle swelling and breathlessness associated with a 30% fall
in LVEF between pre- and end-chemo to 30.5%. This patient
responded rapidly to low dose diuretics and fluid restriction and
was assessed by the cardiology team with full recovery of cardiac
function within 2 weeks.
Cardiac Energetics Assessed by 31P-MRS
31P MR spectra were successfully acquired for 19 breast cancer
patients pre-chemotherapy, 11 at mid-chemotherapy, and 17
end-chemotherapy. Missing scans were due to inter-current
illness or technical issues for one participant at the pre-
chemotherapy scan, four mid-chemotherapy, and two end-
chemotherapy. An example patient 31P spectrum is shown
in Figure 1. There was no significant difference in the mean
PCr/ATP ratio between healthy controls and patients at the pre-
chemo time point (1.94 ± 0.42 vs. 2.16 ± 0.46, respectively, p =
0.11).
For the patient cohort there was no significant difference
in mean sequential values for PCr/ATP ratio comparing pre-,
mid-, and end-chemotherapy time-points. However, there was a
significant negative correlation between the change in PCr/ATP
from pre- to mid-chemotherapy and the subsequent change in
PCr/ATP from mid- to end chemotherapy (r =−0.68, p= 0.04).
The mean change in the PCr/ATP ratio at mid- and at end-
chemotherapy relative to the mean baseline value is plotted in
Figure 3.
Plasma High Sensitivity Cardiac Troponin-I
Plasma cardiac cTn-I-I levels (ng/L) were low-normal (<5 ng/L)
in all patients at baseline prior to starting chemotherapy and
increased progressively by mid-chemo with a further rise at the
time of the last chemo cycle (Figure 4). The threshold cTn-I level
for identifying acute coronary syndrome (ACS) in women in our
center is 16 ng/L and is based on the 99th upper centile of the
normal range for a large sample of patients (15). In our study,
while all participants showed a small but significant rise in mean
cTn-I value between baseline andmid-chemo (1.35± 0.81 to 4.40
± 2.64 ng/L, p = 0.0001) none of these values exceeded the ACS
threshold (16 ng/L). By end-chemo there was a further significant
increase in mean plasma cTn-I (4.40± 2.64 to 14.84± 8.73 ng/L,
p= 0.0001) with six cTn-I values above the ACS threshold. These
six patients, and a further three patients with borderline normal
cTnI levels at end-chemo, were invited back 2–3 months after
end of chemotherapy for longer term follow-up with repeat blood
cTn-I. In all cases cTn-I had returned to normal level (mean ±
SD, 1.55± 0.88 ng/L).
The specific type of chemotherapy regime had no impact on
cTn-I levels. At mid-chemotherapy cTn-I was not significantly
higher in patients receiving FEC-T compared to FEC80 (5.0 ±
FIGURE 3 | PCr/ATP ratio in healthy volunteers and in breast cancer patients
during chemotherapy. Myocardial PCr/ATP ratio (box and whiskers plot) in
healthy volunteers (blue) and in breast cancer patients (black) pre, mid, and at
end of chemotherapy [p = 0.80 for pre-chemo vs. mid-chemo and p = 0.99
for pre to end chemo (one-way ANOVA with Tukey multiple comparison test)].
FIGURE 4 | Plasma cardiac troponin levels during chemotherapy in breast
cancer patients. High sensitivity cardiac troponin-I levels pre-, mid-, and
end-chemotherapy [box and whiskers plot, **indicates P < 0.001 for change
from pre-chemo (paired t-test)] and at 2–3 months follow-up in patients with
values above the normal range at end-chemo (n = 9).
2.9 vs. 3.0 ± 0.89 ng/L, respectively, p = 0.12) or at end-chemo
in patients receiving FEC80 compared to those receiving FEC-
T (18.3 ± 12.0 vs. 13.2 ± 6.7 ng/L, respectively, p = 0.24). As
expected, the side of the cancer had no impact on cTn-I levels
at any of the time points studied (end-chemo: left 15.1 ± 8.1 vs.
right 15.5± 10.1, p= 0.92).
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Electrocardiograms (ECG)
There were no significant changes in PR interval or QRS duration
during chemotherapy. There was a small but significant increase
in the corrected QT interval (QTc) from 422 ± 15 to 438 ±
13ms (p = 0.0001) with most of this increase occurring between
baseline and mid-chemo. Overall, no patient showed an increase
of QTc of >60ms or a QTc above 500 ms.
Exploratory Analysis of Possible
Association Between LVEF, PCr/ATP, QT
Interval, and Cardiac Troponin-I
A significant negative correlation was found between the change
in PCr/ATP ratio and the change in LVEF from pre-chemo
to end-chemo (r = −0.65, p = 0.006, Supplementary Figure).
A significant negative correlation was also found between the
change in PCr/ATP ratio from pre- to end-chemotherapy and
the change in LVEF frommid- to end-chemotherapy (r =−0.77,
p = 0.002). There was no apparent association between cTn-I
and LVEF or PCr/ATP any of the time points. There was also no
association found between changes in the corrected QT interval
in the electrocardiogram and changes in cTn-I or changes in the
QT interval and changes in LVEF. There was no apparent effect
of trastuzumab treatment on cTn-I levels.
In total, six patients displayed cTn-I values above the
normal range at the end-chemo timepoint. When examining
each of these patients on an individual basis, no clear
relationship was observed between cTn-I and baseline clinical
data, including pre-existing hypertension or smoking history,
LVEF or PCr/ATP ratio.
DISCUSSION
This study has explored the applicability of PCr/ATP ratio,
measured using 31P MRS, to detect early anthracyclines-induced
cardiac injury in a pilot cohort. The widely accepted cellular
mechanism underlying anthracycline-induced cardiac toxicity
is based on generation of reactive oxygen species (ROS)
resulting from mitochondrial damage associated with elevated
intracellular iron (19). Such damage to mitochondria is likely
to cause early perturbations in high energy phosphates within
cardiomyocytes and hence is the rationale for assessing 31P-
MRS in this clinical setting. In addition, cardiotoxicity associated
with breast cancer treatment is categorized as either type I,
associated with irreversible cardiomyocyte death, or type II due
to reversible cardiomyocyte dysfunction (9). Impaired cardiac
energetics could represent a possible underlying mechanism for
type II toxicity.
We compared PCr/ATP ratio with other markers of
cardiotoxicity including high sensitivity plasma cardiac Tn-
I, ECG parameters, and cardiac magnetic resonance imaging
assessment of LVEF.While these conventional factors suggested a
progressive cardiotoxic effect of chemotherapy there was no clear
signal in the PCr/ATP ratio data. The possible reasons for this
are discussed.
Cardioprotection during chemotherapy has been
demonstrated using ACE inhibitors (20), statins (21), angiotensin
receptor antagonists (22), but not metoprolol (22). Dexrazoxane
has been shown to reduce cardiac troponin release during
anthracycline based chemotherapy (23). Only two patients in our
study received ACE inhibitors for management of high blood
pressure and hence background drug therapy is unlikely to have
impacted our findings. Allopurinol (24) andmetformin (25) have
also been shown to affect cardiac energetics and these possibly
merit further study using 31P-MRS to assess their mechanism of
action during chemotherapy.
Patient specific factors such as age and physical fitness are
also known to affect PCr/ATP ratio. Jakovljevic et al. (26) found
that PCr/ATP ratio was significantly reduced in older compared
to younger women. They also found that older women who
are physically active maintained high PCr/ATP ratios similar
to younger sedentary women. Genetic factors are also known
to play a part in susceptibility to cardiotoxicity in response to
chemotherapy (27). Therefore, physical activity, pre-treatment
levels of physical fitness, and genetics could provide intrinsic
protection during chemotherapy, potentially impacting on the
effects of chemotherapy on PCr/ATP.
While we observed a significant decrease in LVEF between pre
and end chemotherapy by approximately 5% we also observed
a negative association between changes in PCr/ATP ratio and
LVEF between pre- and end-chemotherapy. This finding is not
consistent with studies in dilated cardiomyopathy (unrelated to
anthracyclines) where low PCr/ATP ratios were associated with
reduced LVEF (28, 29) and while this was a pilot study, we
had predicted a fall in PCr/ATP ratios in line with or perhaps
preceding a fall in LVEF. The reasons for this are not clear. There
is possibly a more complex relationship between energetics and
LVEF in the setting of anthracycline chemotherapy compared
to other forms of cardiomyopathy or the relatively modest
reduction in mean LVEF of 5% was not sufficient to reveal a
measurable change in PCr/ATP ratio during the course of the
chemotherapy regimen. A further reason for the lack of clear
change in PCr/ATP ratio is the possibility of a type 2 statistical
error. Since the number of patients clinically well enough to
have a 31P-MRS scan at mid-chemo time point fell from 20 to
11, this small number was at the predicted limit to allow us
to detect a significant change in PCr/ATP ratio. Furthermore,
this mid-chemo time point was important in that all 20 patients
had been receiving anthracyclines over the previous 6 weeks
in the run up to this mid-point scan. Thereafter, most patients
(14) switched to docetaxel for the last three chemo-cycles thus
diminishing our chances of detecting an effect on the final scan.
It is therefore possible that cardiac energetics recovered in the 14
patients treated with Docetaxel for the final three chemo cycles.
In addition, the relatively low cumulative dose of anthracyclines
used may have limited cardiotoxicity.
Overall, the fall in LVEF, increase in QT interval on ECG and
the rise in cardiac troponin together suggest that there was some
degree of cardiac toxicity in our cohort. The very slight fall in
PCr/ATP ratio at mid-chemo, while non-significant, is therefore
highly intriguing and merits further study addressing the issues
highlighted in our pilot. Furthermore, the sensitivity of 31P-MRS
scans could be significantly improved by using higher magnetic
field strengths (7T) (30, 31).
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CONCLUSIONS
This study investigated 31P MRS in assessing cardiac energetics
of breast cancer patients undergoing chemotherapy in a pilot
cohort. Our findings have highlighted the challenges of serial
cardiac imaging studies during complex chemotherapy regimens
and outlined a pathway by which this technique could be
further explored to establish its potential for detection of
cardiac energetics during chemotherapy. Future studies should
take account of a potentially high level of patient drop-out,
background factors that could influence cardiac PCr/ATP ratio,
such as age, physical fitness, and regular medications, and should
seek to improve sensitivity using 7T MRI. Future studies could
include assessment of Trastuzumab on 31P MR myocardial
imaging and changes in T1 and T2 mapping.
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